Key facts, as of
As of November 9, 2026, DexCom Inc. (DXCM) trades at $81.07, up 47.4% over the past year. Its 52-week range runs from $54.20 to $92.59; the price is 12.4% below that high. It is 50.8% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +320.7%, against +316.3% for the S&P 500 (SPY). It sits 8.2% above its 200-day average of $74.93. Its 30-day volatility is 50.9% annualized, which we rate very high risk. It has a trailing P/E of 31.9.
Cite: Portfolio Terminal, "DexCom Inc. (DXCM) stock analysis", 2026-11-09. https://portfolio-terminal.com/analyse/dxcm
Where it trades today
trading 70% of the way up its 52-week range
How the price has moved
How far it is from its record
DexCom Inc. (DXCM) is 50.8% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +320.7%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- DXCM closes below its 50-day average ($85.01) while the 50-day is still above the 200-day ($74.93): a pullback inside a longer rise, not yet a downtrend.
- At $81.07, DXCM is 12.4% below its 1-year high of $92.59, set on August 24, 2026, and 49.8% above its 1-year low of $54.11 (November 7, 2025).
- Over the past month DXCM fell 3.6%, from $84.11 to $81.07.
- DXCM trades at 31.9x its last twelve months of earnings and 25.9x the next twelve months' estimate, so analysts expect earnings 23.4% higher.
- Its P/E is 8.0% below the 34.7x median of the 3 other medical devices companies we track (ABT, SYK, BSX).
- DXCM's 30-day volatility, 50.9% a year, works out to a typical daily move of about 3.2%.
- Yahoo Finance puts its beta at 1.44: over five years of monthly returns, DXCM moved about 1.44% for each 1% move of the S&P 500.
What would change the read
- A close back above the 50-day average, $85.01 (+4.9%), restores the uptrend; the 50-day falling 11.9% under the 200-day at $74.93 would make it a downtrend.
- A close above $92.59 (+14.2%) would be a new 1-year high; below $54.11 (−33.3%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for DXCM, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for DXCM by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for DXCM. Last refresh: Nov 9, 2026, 9:37 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What DexCom Inc. does
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and…
What analysts expect
DXCM carries a strong buy consensus from 26 analysts, with an average price target of $98.15 versus $81.07 today (+21.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
DXCM generated $5.10B in trailing revenue (11.2% year over year), with a 19.4% net margin, and $811.90M of free cash flow, supported by $425.00M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $4.66B | $2.80B | $911.80M | $836.30M | $2.14 | $1.08B |
| 2024 | $4.03B | $2.44B | $600.00M | $576.20M | $1.46 | $630.70M |
| 2023 | $3.62B | $2.29B | $597.70M | $541.50M | $1.40 | $511.90M |
| 2022 | $2.91B | $1.88B | $391.20M | $341.20M | $0.88 | $304.70M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
DXCM is in 22 of the 54 ETFs we track. It weighs most in XLV: 0.51% of the fund, holding #41 of 62.
Famous investors who hold it
DXCM is in the latest 13F of 2 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.15% of the portfolio, position #139 of 2,931, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
DXCM beside the other companies Yahoo Finance files under medical devices among the assets we track (ABT, SYK, BSX, largest first).
DXCMyou are here$81.07$30.24B
ABTAbbott Laboratories$110.51$191.40B
SYKStryker Corporation$325.73$124.00B
BSXBoston Scientific$44.02$63.81BWhat the chart is saying
Slipped under its 50-day average inside a longer uptrend.
weakening- Price is 4.6% below its 50-day average and 8.2% above its 200-day.
- The 50-day crossed above the 200-day on 2026-06-29 (a “golden cross”).
- RSI at 46 is neither stretched nor washed out.
- The nearest ceiling is $82.58 (+1.9%), the nearest floor $79.03 (-2.5%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is DXCM valued right now?
DexCom Inc. trades at 31.9 times its last twelve months of earnings and 25.9 times the next twelve months' estimate (Yahoo Finance, November 9, 2026). On the chart: slipped under its 50-day average inside a longer uptrend. Price is 4.6% below its 50-day average and 8.2% above its 200-day.
What is the risk level of DXCM?
Based on 30-day volatility of 50.9%, DXCM has VERY HIGH risk. Its beta of 1.44 means it has swung more than the S&P 500 over the last five years.
Does DXCM pay dividends?
Yahoo Finance shows no dividend yield for DexCom Inc. (November 9, 2026).
How far is DXCM from its all-time high?
DexCom Inc. is 50.8% below its all-time high of $164.86, reached in November 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +320.7%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold DXCM?
22 of the 54 popular ETFs we track hold DexCom Inc.. The largest weights: XLV (0.51%), VO (0.32%), RSP (0.20%), JEPQ (0.19%) and QQQM (0.14%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is DXCM?
0.05%, as of September 30, 2026: DXCM is holding #288 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.49 in DexCom Inc..
Which famous investors own DXCM?
Renaissance Technologies (0.15% of Founded by Jim Simons's 13F) and Ray Dalio (0.11% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for DXCM?
The average analyst price target for DexCom Inc. (DXCM) is $98.15 based on 26 analyst estimates, about 21.1% above the current price of $81.07. The published range runs from $79.00 to $120.00.
How much revenue does DXCM generate?
DexCom Inc. reported $5.10B in trailing twelve-month revenue. Revenue growth is running at 11.2% year over year. Net margin sits at 19.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare DXCM with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.